Bristol-Myers Squibb Company

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, LLY has a market cap of 663.7B. Regarding current trading prices, BMY is priced at $47.81, while LLY trades at $684.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas LLY's P/E ratio is 45.77. In terms of profitability, BMY's ROE is +0.30%, compared to LLY's ROE of +0.88%. Regarding short-term risk, BMY is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.Check LLY's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, JNJ has a market cap of 425.4B. Regarding current trading prices, BMY is priced at $47.81, while JNJ trades at $174.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas JNJ's P/E ratio is 18.93. In terms of profitability, BMY's ROE is +0.30%, compared to JNJ's ROE of +0.30%. Regarding short-term risk, BMY is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.Check JNJ's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, ABBV has a market cap of 365.2B. Regarding current trading prices, BMY is priced at $47.81, while ABBV trades at $204.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas ABBV's P/E ratio is 97.97. In terms of profitability, BMY's ROE is +0.30%, compared to ABBV's ROE of +0.86%. Regarding short-term risk, BMY is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.Check ABBV's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, AZN has a market cap of 245.4B. Regarding current trading prices, BMY is priced at $47.81, while AZN trades at $78.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas AZN's P/E ratio is 29.88. In terms of profitability, BMY's ROE is +0.30%, compared to AZN's ROE of +0.20%. Regarding short-term risk, BMY is more volatile compared to AZN. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.Check AZN's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, NVS has a market cap of 240.5B. Regarding current trading prices, BMY is priced at $47.81, while NVS trades at $122.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas NVS's P/E ratio is 18.11. In terms of profitability, BMY's ROE is +0.30%, compared to NVS's ROE of +0.23%. Regarding short-term risk, BMY is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.Check NVS's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, NVO has a market cap of 232.9B. Regarding current trading prices, BMY is priced at $47.81, while NVO trades at $50.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas NVO's P/E ratio is 13.51. In terms of profitability, BMY's ROE is +0.30%, compared to NVO's ROE of +0.78%. Regarding short-term risk, BMY is less volatile compared to NVO. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.Check NVO's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, MRK has a market cap of 210.4B. Regarding current trading prices, BMY is priced at $47.81, while MRK trades at $82.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas MRK's P/E ratio is 12.98. In terms of profitability, BMY's ROE is +0.30%, compared to MRK's ROE of +0.36%. Regarding short-term risk, BMY is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.Check MRK's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, AMGN has a market cap of 159.6B. Regarding current trading prices, BMY is priced at $47.81, while AMGN trades at $290.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas AMGN's P/E ratio is 24.26. In terms of profitability, BMY's ROE is +0.30%, compared to AMGN's ROE of +0.98%. Regarding short-term risk, BMY is more volatile compared to AMGN. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.Check AMGN's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, GILD has a market cap of 146.9B. Regarding current trading prices, BMY is priced at $47.81, while GILD trades at $119.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas GILD's P/E ratio is 15.29. In terms of profitability, BMY's ROE is +0.30%, compared to GILD's ROE of +0.33%. Regarding short-term risk, BMY is more volatile compared to GILD. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.Check GILD's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, PFE has a market cap of 143B. Regarding current trading prices, BMY is priced at $47.81, while PFE trades at $25.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas PFE's P/E ratio is 13.31. In terms of profitability, BMY's ROE is +0.30%, compared to PFE's ROE of +0.12%. Regarding short-term risk, BMY is more volatile compared to PFE. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.Check PFE's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, SNY has a market cap of 123.4B. Regarding current trading prices, BMY is priced at $47.81, while SNY trades at $49.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas SNY's P/E ratio is 16.53. In terms of profitability, BMY's ROE is +0.30%, compared to SNY's ROE of +0.12%. Regarding short-term risk, BMY is more volatile compared to SNY. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.Check SNY's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, CELG-RI has a market cap of 99.8B. Regarding current trading prices, BMY is priced at $47.81, while CELG-RI trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, BMY's ROE is +0.30%, compared to CELG-RI's ROE of +0.30%. Regarding short-term risk, BMY is more volatile compared to CELG-RI. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.Check CELG-RI's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, GSK has a market cap of 80.2B. Regarding current trading prices, BMY is priced at $47.81, while GSK trades at $39.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas GSK's P/E ratio is 17.63. In terms of profitability, BMY's ROE is +0.30%, compared to GSK's ROE of +0.24%. Regarding short-term risk, BMY is more volatile compared to GSK. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.Check GSK's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, BMY is priced at $47.81, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas HZNP's P/E ratio is 61.86. In terms of profitability, BMY's ROE is +0.30%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, BMY is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for BMY.Check HZNP's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, BIIB has a market cap of 20.3B. Regarding current trading prices, BMY is priced at $47.81, while BIIB trades at $134.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas BIIB's P/E ratio is 13.28. In terms of profitability, BMY's ROE is +0.30%, compared to BIIB's ROE of +0.09%. Regarding short-term risk, BMY is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.Check BIIB's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, GRFS has a market cap of 9.1B. Regarding current trading prices, BMY is priced at $47.81, while GRFS trades at $10.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas GRFS's P/E ratio is 21.02. In terms of profitability, BMY's ROE is +0.30%, compared to GRFS's ROE of +0.05%. Regarding short-term risk, BMY is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.Check GRFS's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, OGN has a market cap of 2.5B. Regarding current trading prices, BMY is priced at $47.81, while OGN trades at $9.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas OGN's P/E ratio is 3.51. In terms of profitability, BMY's ROE is +0.30%, compared to OGN's ROE of +0.99%. Regarding short-term risk, BMY is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.Check OGN's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, CTOR has a market cap of 132.4M. Regarding current trading prices, BMY is priced at $47.81, while CTOR trades at $1.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas CTOR's P/E ratio is -4.33. In terms of profitability, BMY's ROE is +0.30%, compared to CTOR's ROE of -0.68%. Regarding short-term risk, BMY is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.Check CTOR's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, SCLX has a market cap of 125.8M. Regarding current trading prices, BMY is priced at $47.81, while SCLX trades at $17.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas SCLX's P/E ratio is -1.16. In terms of profitability, BMY's ROE is +0.30%, compared to SCLX's ROE of +0.57%. Regarding short-term risk, BMY is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.Check SCLX's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, SCLXW has a market cap of 120.8M. Regarding current trading prices, BMY is priced at $47.81, while SCLXW trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas SCLXW's P/E ratio is N/A. In terms of profitability, BMY's ROE is +0.30%, compared to SCLXW's ROE of +0.57%. Regarding short-term risk, BMY is less volatile compared to SCLXW. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.Check SCLXW's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, MIRA has a market cap of 28.6M. Regarding current trading prices, BMY is priced at $47.81, while MIRA trades at $1.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas MIRA's P/E ratio is -3.19. In terms of profitability, BMY's ROE is +0.30%, compared to MIRA's ROE of -3.41%. Regarding short-term risk, BMY is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.Check MIRA's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, SRXH has a market cap of 15.9M. Regarding current trading prices, BMY is priced at $47.81, while SRXH trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas SRXH's P/E ratio is N/A. In terms of profitability, BMY's ROE is +0.30%, compared to SRXH's ROE of -0.50%. Regarding short-term risk, BMY is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.Check SRXH's competition here

BMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMY stands at 98.7B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, BMY is priced at $47.81, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMY currently has a P/E ratio of 19.47, whereas CRXT's P/E ratio is -0.02. In terms of profitability, BMY's ROE is +0.30%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, BMY is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for BMY.Check CRXT's competition here